GleamWall
中文EN

LONA LeonaBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1620463 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-313.6%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-729.0%
ROA-457.7%
ROIC (approx.)-3,861.7%
Asset turnover—

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.00x
Current ratio4.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-234.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$15.02M$12.70M$11.26M$6.71M$2.83M$3.66M$4.30M$9.37M
SG&A expense$6.86M$6.58M$6.88M$3.77M$4.05M$3.63M$5.23M$6.20M
Operating income-$21.47M-$19.45M-$17.21M-$78.56M-$6.87M-$7.29M-$9.54M-$15.57M
Net income-$21.16M-$19.01M-$32.95M-$82.89M-$6.61M-$6.97M-$9.14M-$15.00M
EBITDA-$21.27M-$19.25M-$16.98M-$78.32M-$6.67M-$7.09M-$9.29M-$15.32M
EPS (basic)-0.89-0.80-1.73—-1.68-1.78-2.34—
EPS (diluted)-0.89-0.80-1.73—-1.68-1.78-2.34—
Weighted avg. shares (diluted)23.74M23.73M19.03M—3.94M3.91M3.90M—
Balance sheet
Cash & equivalents$16.34M$32.32M$32.83M$69.28M$20.87M$19.89M$26.42M$48.44M
Short-term investments$15.97M$18.74M$34.85M$19.05M$4.35M$9.94M$10.25M$2.84M
Current assets$36.33M$54.81M$69.20M$89.46M$27.02M$32.22M$39.85M$54.84M
PP&E, net$800,000$1.01M$1.24M$1.47M$1.72M$1.96M$2.20M$2.44M
Total assets$38.14M$56.89M$71.59M$92.15M$30.03M$35.55M$43.51M$58.78M
Current liabilities$7.33M$7.82M$6.67M$47.50M$2.79M$2.98M$5.49M$13.13M
Total liabilities$22.12M$23.30M$22.29M$64.36M$3.25M$3.56M$6.18M$13.94M
Shareholders' equity$16.02M$33.59M$49.30M$27.79M$26.79M$31.99M$37.33M$44.84M
Shares outstanding9.93M9.42M9.39M9.34M3.94M39.44M39.04M3.90M
Cash flow statement
Operating cash flow-$18.89M-$16.96M-$20.90M-$19.40M-$4.67M-$7.00M-$14.66M-$26.01M
Capital expenditure———————$0
Free cash flow———————-$26.01M
Investing cash flow$2.91M$16.33M-$15.54M-$14.64M$5.65M$441,000-$7.35M-$2.81M
Financing cash flow$0——$82.44M$0——$34,000
Depreciation & amortization$200,000$200,000$231,000$243,000$200,000$200,000$243,000$243,000
Stock-based compensation$3.59M$3.18M$662,000$1.46M$1.41M$1.60M$1.64M$2.23M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.